Peritoneal Carcinomatosis

Peritoneal carcinomatosis describes cancer spread involving the peritoneum, the membrane lining the abdominal cavity. It is not usually a primary disease in itself but rather a manifestation of underlying malignancy, commonly from ovarian, colorectal, gastric, appendiceal, or other abdominal cancers. ^[1][2]

What is peritoneal carcinomatosis?

Peritoneal carcinomatosis refers to dissemination of malignant cells across the peritoneal surfaces within the abdomen. Instead of forming one isolated mass, cancer may seed multiple areas of the peritoneum and lead to nodules, fluid accumulation, bowel-related complications, and systemic decline. It is therefore not simply “a tumor in the abdomen,” but a particular pattern of metastatic spread with distinct clinical implications. In some malignancies, especially certain ovarian and gastrointestinal cancers, peritoneal spread is a major part of the disease burden. ^[1][2][3]

What symptoms can occur?

Symptoms may be subtle at first and often become more apparent as disease burden increases. Abdominal distention, increasing abdominal girth, discomfort, early satiety, nausea, changes in bowel habits, weight loss, fatigue, and fluid accumulation in the abdomen are common. Some people develop bowel obstruction, more pronounced pain, or progressive weakness. Because these symptoms are nonspecific, they may be mistaken for gastrointestinal or gynecologic disorders early on. Persistent abdominal bloating, unexplained ascites, or progressive constitutional symptoms warrant careful evaluation. ^[1][2][5]

How is it diagnosed?

Diagnosis usually involves imaging, clinical history, examination, and sometimes pathology. CT is commonly used, but imaging may not always show the full extent of disease. In some cases, PET imaging, MRI, diagnostic laparoscopy, pathology review, tumor markers, and evaluation of ascitic fluid may contribute to diagnosis and staging. The aim is to identify the primary malignancy when possible, estimate the extent of peritoneal involvement, and determine which treatment strategies remain appropriate. ^[1][2][4]

How is treatment planned?

Treatment depends on the primary cancer, disease distribution, the patient’s overall condition, symptom burden, and treatment goals. In some selected patients, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered. In other cases, systemic therapy, symptom control, drainage of ascites, nutritional support, or palliative care may be more appropriate. There is no single treatment path for all patients. The key is to match the treatment plan to tumor biology, functional status, and realistic benefit. ^[1][2][6]

Why are ascites and bowel symptoms important?

Ascites can cause abdominal pressure, difficulty eating, shortness of breath, and reduced mobility. Bowel symptoms are important because peritoneal metastasis may impair intestinal movement or cause obstruction. These complications are not only uncomfortable; they can also become urgent medical problems. Prompt attention to worsening vomiting, inability to tolerate food, increasing distention, or severe abdominal pain is therefore essential. ^[1][2][5]

Is treatment always intended to be curative?

No. In some patients, the realistic goal is symptom control, maintenance of quality of life, and reduction of disease burden rather than complete eradication of disease. In carefully selected situations, more aggressive approaches may offer meaningful benefit, but this is not appropriate or effective for every case. Clear discussion of goals of care is therefore an important part of management. ^[1][6]

When should urgent medical attention be sought?

Urgent evaluation is appropriate for severe abdominal pain, vomiting with inability to eat or drink, progressive abdominal distention, signs of bowel obstruction, dehydration, fever, or sudden worsening of general condition. In a patient with known cancer, new or rapidly worsening abdominal symptoms should not simply be observed at home. Timely reassessment may help address both treatable complications and symptom relief needs. ^[1][2][5]

FAQ

Is peritoneal carcinomatosis a primary cancer?
Usually no. It most often represents spread from another malignancy. ^[1][2]

Can it cause ascites?
Yes. Ascites is a common manifestation and may contribute significantly to symptoms. ^[1][2]

Does every patient qualify for HIPEC?
No. Suitability depends on cancer type, disease extent, performance status, and overall treatment strategy. ^[1][2]

Can symptoms begin gradually?
Yes. Symptoms may be nonspecific and may progress over time. ^[1][5]

Is the treatment goal always complete recovery?
No. In some patients, the main goal is symptom control, quality of life, and reduction of disease burden. ^[1][6]